EE200400031A - Biokeemiliste ühendite kompositsioon, selle kasutamine maatriks-metalloproteinaaside pärssimiseks ning seda sisaldav ravimpreparaat - Google Patents

Biokeemiliste ühendite kompositsioon, selle kasutamine maatriks-metalloproteinaaside pärssimiseks ning seda sisaldav ravimpreparaat

Info

Publication number: EE200400031A
Authority: EE; Estonia
Prior art keywords: composition; pharmaceutical formulation; formulation containing; matrix metalloproteinases; biochemical compounds
Prior art date: 2002-01-08

Application number

EEP200400031A

Other languages

English (en)

Inventor

Rath Matthias

Netke Shrirang

Ivanov Vadim

Roomi Waheed

Niedzwiecki Aleksandra

Original Assignee

Rath Matthias

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-08

Filing date

2002-01-31

Publication date

2004-04-15

2002-01-31 Application filed by Rath Matthias filed Critical Rath Matthias

2004-04-15 Publication of EE200400031A publication Critical patent/EE200400031A/et

Links

239000000203 mixture Substances 0.000 title abstract 3
102000002274 Matrix Metalloproteinases Human genes 0.000 title 1
108010000684 Matrix Metalloproteinases Proteins 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 4
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
239000004472 Lysine Substances 0.000 abstract 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 2
229960005070 ascorbic acid Drugs 0.000 abstract 2
235000010323 ascorbic acid Nutrition 0.000 abstract 2
239000011668 ascorbic acid Substances 0.000 abstract 2
ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 abstract 2
235000005487 catechin Nutrition 0.000 abstract 2
-1 catechin compound Chemical class 0.000 abstract 2
229950001002 cianidanol Drugs 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000001613 neoplastic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Neurology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Inorganic Chemistry (AREA)
Biotechnology (AREA)
Vascular Medicine (AREA)
AIDS & HIV (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)

EEP200400031A 2002-01-08 2002-01-31 Biokeemiliste ühendite kompositsioon, selle kasutamine maatriks-metalloproteinaaside pärssimiseks ning seda sisaldav ravimpreparaat EE200400031A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10/041,427 US6939860B2 (en)	2002-01-08	2002-01-08	Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds
PCT/EP2002/001005 WO2003057211A1 (en)	2002-01-08	2002-01-31	Composition inhibiting matrix-metallproteinases for the treatmentof neoplastic diseases.

Publications (1)

Publication Number	Publication Date
EE200400031A true EE200400031A (et)	2004-04-15

Family

ID=21916454

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200400031A EE200400031A (et)	2002-01-08	2002-01-31	Biokeemiliste ühendite kompositsioon, selle kasutamine maatriks-metalloproteinaaside pärssimiseks ning seda sisaldav ravimpreparaat

Country Status (29)

Country	Link
US (3)	US6939860B2 (et)
EP (1)	EP1463498B1 (et)
JP (1)	JP4144800B2 (et)
KR (1)	KR20050005408A (et)
CN (1)	CN1612731A (et)
AT (1)	ATE439833T1 (et)
AU (2)	AU2002244690A1 (et)
BR (1)	BR0208052A (et)
CA (1)	CA2469162A1 (et)
CZ (1)	CZ2004853A3 (et)
DE (1)	DE60233433D1 (et)
EE (1)	EE200400031A (et)
ES (1)	ES2332126T3 (et)
HR (1)	HRP20040705A2 (et)
HU (1)	HUP0402421A3 (et)
IL (1)	IL162384A0 (et)
LT (1)	LT5215B (et)
LV (1)	LV13249B (et)
MX (1)	MXPA04006627A (et)
NO (1)	NO20033949L (et)
NZ (1)	NZ533353A (et)
PL (1)	PL371205A1 (et)
RU (1)	RU2284185C2 (et)
SI (1)	SI21871A (et)
SK (1)	SK2772004A3 (et)
TR (1)	TR200401669T1 (et)
UA (1)	UA78979C2 (et)
WO (1)	WO2003057211A1 (et)
ZA (1)	ZA200404915B (et)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8669282B2 (en) *	2000-10-31	2014-03-11	Hill's Pet Nutrition, Inc.	Companion animal compositions including lipoic acid and methods of use thereof
US6939860B2 (en) *	2002-01-08	2005-09-06	Matthias Rath	Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds
US20050079234A1 (en) *	2003-08-27	2005-04-14	Chiang Yang Chi	Compositions comprising herbs and method for immunomodulation
KR20050070385A (ko) *	2003-12-30	2005-07-07	(주)현덕비엔티	폴리페놀과, 아스코르빈산 또는 그 유도체를 함유하는항암치료 보조용 조성물
US20080160099A1 (en) *	2004-11-10	2008-07-03	The Trustees Of Columbia University In The City Of New York	Methods For Treating or Preventing a Vascular Disease
ES2246737B1 (es) *	2005-06-09	2006-12-01	Jose Juan Rodriguez Jerez	"composicion farmaceutica que comprende lisina y usos correspondientes".
EP1965779B1 (en) *	2005-12-29	2014-07-02	Mitsui Norin Co., Ltd	Compositions and methods of sensitizing methicillin resistantstaphylococcus aureus to oxacillin
US20070265211A1 (en) *	2006-05-12	2007-11-15	Matthias Rath	Novel composition and method effective in inhibiting the atherogenic process
US20100055205A1 (en) *	2008-08-29	2010-03-04	Kristina Mains	Functional consumable compositions for promoting skin health and methods for using the same
EP2179722A1 (en) *	2008-10-24	2010-04-28	Heinrich-Pette-Institut für experimentelle Virologie und Immunologie	Topical formation for preventing sexual transmission of viral infection
MX2011004678A (es)	2008-11-04	2011-10-11	Vymedic Llc	Formulaciones complementarias antivirales.
JP4786000B2 (ja) *	2009-10-16	2011-10-05	株式会社カネカ	還元型補酵素ｑ１０の製造方法、安定化方法及びそれを含有する組成物
ES2694582T3 (es) *	2011-01-31	2018-12-21	Lucolas-M.D. Ltd.	Combinaciones de inhibidores de aromatasa y antioxidantes
KR101829330B1 (ko)	2011-04-13	2018-02-20	(주)아모레퍼시픽	염증성 피부 노화 억제 물질 스크리닝 방법
CN102526170B (zh) *	2011-12-31	2015-04-29	许学志	抗结核杆菌的儿茶提取物组合物、其制备方法及含有它们的药物制剂和应用
BE1023772B9 (fr) *	2013-05-17	2017-08-02	Valore	Composition a base d'un complexe de (+)-catechine et d'acide amine pour le traitement et la prevention du cancer
CN104096058A (zh) *	2014-07-02	2014-10-15	胥玲	一种治疗扩张型心肌病的中药药丸
BE1022579A9 (fr) *	2014-11-10	2016-10-06	Valore	Composition antimétastatique comprenant au moins un composé de type flavanol
IT202200013867A1 (it) *	2022-06-30	2023-12-30	Lo Li Pharma Srl	Composizione per il trattamento dell’ infezione da papilloma virus (hpv)
CN118831080B (zh) *	2024-09-24	2024-11-22	上海交通大学医学院附属仁济医院	5-氧脯氨酸在制备预防或治疗心肌病的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5863949A (en) *	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
HUP9903916A3 (en) *	1996-08-28	2001-06-28	Procter And Gamble Co Cincinna	Phosphinic acid amides and pharmaceutical compositions containing the same
US5962517A (en) *	1997-01-31	1999-10-05	Murad; Howard	Pharmaceutical compositions and methods for treating acne
US5817695A (en) *	1997-12-24	1998-10-06	Pellico; Michael A.	Nutritional product with high fat, low carbohydrate and amino acid imbalance
US6428818B1 (en) *	1999-03-30	2002-08-06	Purdue Research Foundation	Tea catechin formulations and processes for making same
KR20020016833A (ko)	1999-06-15	2002-03-06	뉴트리-로직스, 인크.	발병 감소에 유용한 영양 제제, 관련 치료 방법 및 성분스크리닝 방법
US6939860B2 (en) *	2002-01-08	2005-09-06	Matthias Rath	Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds
EP1480973B1 (en) *	2002-02-25	2008-02-13	Boehringer Ingelheim Pharmaceuticals Inc.	1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases

2002
- 2002-01-08 US US10/041,427 patent/US6939860B2/en not_active Expired - Fee Related
- 2002-01-31 EE EEP200400031A patent/EE200400031A/et unknown
- 2002-01-31 WO PCT/EP2002/001005 patent/WO2003057211A1/en not_active Ceased
- 2002-01-31 RU RU2004124047/15A patent/RU2284185C2/ru not_active IP Right Cessation
- 2002-01-31 AT AT02712877T patent/ATE439833T1/de active
- 2002-01-31 KR KR10-2004-7010603A patent/KR20050005408A/ko not_active Ceased
- 2002-01-31 PL PL02371205A patent/PL371205A1/xx unknown
- 2002-01-31 SI SI200220038A patent/SI21871A/sl not_active IP Right Cessation
- 2002-01-31 ES ES02712877T patent/ES2332126T3/es not_active Expired - Lifetime
- 2002-01-31 NZ NZ533353A patent/NZ533353A/en unknown
- 2002-01-31 JP JP2003557569A patent/JP4144800B2/ja not_active Expired - Fee Related
- 2002-01-31 DE DE60233433T patent/DE60233433D1/de not_active Expired - Lifetime
- 2002-01-31 IL IL16238402A patent/IL162384A0/xx not_active IP Right Cessation
- 2002-01-31 CZ CZ2004853A patent/CZ2004853A3/cs unknown
- 2002-01-31 TR TR2004/01669T patent/TR200401669T1/xx unknown
- 2002-01-31 EP EP02712877A patent/EP1463498B1/en not_active Expired - Lifetime
- 2002-01-31 MX MXPA04006627A patent/MXPA04006627A/es active IP Right Grant
- 2002-01-31 BR BR0208052-4A patent/BR0208052A/pt not_active IP Right Cessation
- 2002-01-31 UA UA20040705480A patent/UA78979C2/uk unknown
- 2002-01-31 HR HR20040705A patent/HRP20040705A2/hr not_active Application Discontinuation
- 2002-01-31 CN CNA028269543A patent/CN1612731A/zh active Pending
- 2002-01-31 AU AU2002244690A patent/AU2002244690A1/en not_active Abandoned
- 2002-01-31 SK SK277-2004A patent/SK2772004A3/sk not_active Application Discontinuation
- 2002-01-31 HU HU0402421A patent/HUP0402421A3/hu unknown
- 2002-01-31 CA CA002469162A patent/CA2469162A1/en not_active Abandoned
2003
- 2003-09-05 NO NO20033949A patent/NO20033949L/no not_active Application Discontinuation
2004
- 2004-06-22 ZA ZA200404915A patent/ZA200404915B/en unknown
- 2004-08-05 LT LT2004074A patent/LT5215B/lt unknown
- 2004-09-06 LV LVP-04-88A patent/LV13249B/en unknown
- 2004-09-15 US US10/942,723 patent/US20050032715A1/en not_active Abandoned
2005
- 2005-08-24 US US11/211,389 patent/US20050281794A1/en not_active Abandoned
2008
- 2008-07-16 AU AU2008203157A patent/AU2008203157A1/en not_active Abandoned

Also Published As

Publication number	Publication date
UA78979C2 (en)	2007-05-10
SK2772004A3 (en)	2004-12-01
RU2284185C2 (ru)	2006-09-27
NO20033949D0 (no)	2003-09-05
ZA200404915B (en)	2006-07-26
ES2332126T3 (es)	2010-01-27
US20050032715A1 (en)	2005-02-10
EP1463498A1 (en)	2004-10-06
US20030130201A1 (en)	2003-07-10
JP4144800B2 (ja)	2008-09-03
DE60233433D1 (de)	2009-10-01
TR200401669T1 (tr)	2007-01-22
AU2008203157A1 (en)	2008-08-07
CZ2004853A3 (cs)	2004-12-15
EP1463498B1 (en)	2009-08-19
LT2004074A (en)	2004-12-27
LT5215B (lt)	2005-05-25
CN1612731A (zh)	2005-05-04
NZ533353A (en)	2007-04-27
JP2005513166A (ja)	2005-05-12
CA2469162A1 (en)	2003-07-17
RU2004124047A (ru)	2005-04-20
LV13249B (en)	2005-07-20
BR0208052A (pt)	2005-01-04
HUP0402421A3 (en)	2008-02-28
IL162384A0 (en)	2005-11-20
MXPA04006627A (es)	2004-11-10
WO2003057211A1 (en)	2003-07-17
US20050281794A1 (en)	2005-12-22
HUP0402421A2 (hu)	2005-07-28
ATE439833T1 (de)	2009-09-15
KR20050005408A (ko)	2005-01-13
PL371205A1 (en)	2005-06-13
HRP20040705A2 (en)	2004-10-31
SI21871A (sl)	2006-04-30
US6939860B2 (en)	2005-09-06
AU2002244690A1 (en)	2003-07-24
NO20033949L (no)	2003-11-04

Publication	Publication Date	Title
EA200501805A1 (ru)	2006-06-30	Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
ATE447574T1 (de)	2009-11-15	3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
EA200300776A1 (ru)	2004-06-24	Производные фенэтаноламина для лечения респираторных заболеваний
MA29387B1 (fr)	2008-04-01	Inhibiteurs de la dipeptidyl peptidase iv
NO20053645L (no)	2002-10-22	(4R)- og (4S)-diastereoisomerer av (2S)-2-[ 2-oksy-4-propylpyrrolidinyl]butanamid og farmasoytisk preparat inneholdende disse
DE60330485D1 (de)	2010-01-21	Zur behandlung von diabetes
BR0310092A (pt)	2005-02-15	Combinação de compostos orgânicos
ECSP055783A (es)	2005-08-11	Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevención de diabetes
BRPI0307351B8 (pt)	2021-05-25	composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
BR0208052A (pt)	2005-01-04	Composição que inibe matriz metaloproteinases para o tratamento de doenças neoplásicas
DE60315687D1 (de)	2007-09-27	Antidiabetische heterocyclische beta-aminoverbindungen als inhibitoren von dipeptidylpeptidase
BR0316723A (pt)	2005-10-18	Derivados de anilinopirazol úteis para o tratamento de diabetes
CY1109366T1 (el)	2014-07-02	Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
BRPI0416287A (pt)	2007-01-23	compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
MXPA05000765A (es)	2005-10-19	Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
DE60301339D1 (de)	2005-09-22	Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
ATE457027T1 (de)	2010-02-15	Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht
ATE432936T1 (de)	2009-06-15	Imidazotriazin verbindungen zur behandlung von krebserkrankungen
NO20080650L (no)	2008-05-13	Forbindelser omfattende DMXAA for behandling av kreft
EE05182B1 (et)	2009-06-15	Asendatud homopiperidlbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
ATE462703T1 (de)	2010-04-15	Bicyclononen-derivate als renin-inhibitoren
BRPI0415497A (pt)	2006-12-26	composto processo para a sua preparação , composição farmacêutica que compreende o mesmo, utilização de um composto e método para o tratamento de diabetes do tipo ii
BR0112123A (pt)	2003-05-06	Composto
DE10390702D2 (de)	2005-01-27	2-Methylthiazolidin-2,4-Dicarbonsäure und deren Salze zur Behandlung von neurodegenerativen Erkrankungen
ATE504332T1 (de)	2011-04-15	Verbindungen, zusammensetzungen, formulierungen und herstellungsverfahren dafür, behandlungsverfahren, handhabung von übersäuerung und verwandte erkrankungen